Friday, July 10, 2026

pharma · Amyotrophic Lateral Sclerosis · Acute Myeloid Leukemia

AB Science

AB Science is a pharma organization headquartered in PARIS, FR. Primary therapeutic focus areas include Amyotrophic Lateral Sclerosis, Acute Myeloid Leukemia, Mastocytosis, Mast cell activation syndrome, Multiple Scleros

PARIS, FR HQ
20 Employees
EMA registrant Type
Company details
Status
Public
HQ
PARIS, FR
Employees
20
Programs
6
Drugs
11
Patents
25
Clinical program

AB19001

Phase 3 · small molecule · Amyotrophic Lateral Sclerosis

AB19001 for Amyotrophic Lateral Sclerosis is a Phase 3 program (small_molecule) at AB Science with 1 ClinicalTrials.gov record(s).

← All AB Science projects Phase 3 small molecule active

Internal code AB19001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
AB Science
Phase
Phase 3
Modality
small_molecule
Indication
Amyotrophic Lateral Sclerosis
Status
active
Trials
1